Axsome Therapeutics (AXSM) Revenue (2022 - 2026)

Axsome Therapeutics (AXSM) has 5 years of Revenue data on file, last reported at $191.2 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 57.42% year-over-year to $191.2 million; the trailing twelve-month figure through Mar 2026 stood at $708.2 million (up 125.63% YoY), and the FY2025 full-year result was $638.5 million, up 65.55% from the prior year.
• Revenue retreated to $191.2 million in Q1 2026, from $196.0 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $196.0 million in Q4 2025 to a low of $500000.0 in Q4 2024.
• A 5-year average of $88.6 million and a median of $81.1 million in 2024 frame the typical range for Revenue.
• Across the five-year window, Revenue plunged 99.3% in 2024 and surged 39099.8% in 2025, its largest moves.
• Tracing AXSM's Revenue over 5 years: stood at $24.4 million in 2022, then surged by 193.5% to $71.5 million in 2023, then sank by 99.3% to $500000.0 in 2024, then surged by 39099.8% to $196.0 million in 2025, then decreased by 2.45% to $191.2 million in 2026.
• Business Quant data shows AXSM's Revenue at $191.2 million in Q1 2026, $196.0 million in Q4 2025, and $171.0 million in Q3 2025.